The Rise and Fall of Antithrombin Supplementation in Cardiac Surgery.
| Autor: | Ranucci M; From the Department of Cardiothoracic and Vascular Anesthesia and Intensive Care, IRCCS Policlinico San Donato, Milan, Italy., Baryshnikova E, Pistuddi V, Di Dedda U |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Anesthesia and analgesia [Anesth Analg] 2023 Jun 01; Vol. 136 (6), pp. 1043-1051. Date of Electronic Publication: 2022 Dec 06. |
| DOI: | 10.1213/ANE.0000000000006314 |
| Abstrakt: | Various cohort studies, both retrospective and prospective, showed that low antithrombin levels after cardiac surgery (at the arrival in the intensive care unit and during the next days) were associated with a number of adverse outcomes, including surgical reexploration and thromboembolic events, eventually leading to prolonged stay in the intensive care. Values lower than 58% to 64% of antithrombin activity were indicative of this higher morbidity with good sensitivity and specificity. The scenario generated the hypothesis that low antithrombin levels needed to be corrected by supplementation to improve postoperative outcome. However, randomized controlled studies run to test this idea failed to demonstrate any benefit of antithrombin supplementation, showing no effects on outcome, neither as preemptive preoperative strategy nor for treating postoperative low antithrombin values. In addition, randomized trials highlighted that those patients who received antithrombin experienced significantly higher incidence of acute kidney injury with a pooled odds ratio of 4.41 (95% CI, 1.90-10.23; P = .001). A strongly decreased thrombin activity after antithrombin correction may eventually affect the efficiency of the glomerular filtration and cause the deterioration of kidney function, but underlying biological mechanisms remain unclear. In conclusion, low levels of antithrombin activity after cardiac surgery should be considered as a marker of greater severity of the patient's conditions and/or of the complexity of the surgical procedure. There are no indications for antithrombin supplementation in cardiac surgery unless for correcting heparin resistance. Competing Interests: Conflicts of Interest: See Disclosures at the end of the article. (Copyright © 2022 International Anesthesia Research Society.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|